Tab. II.
Antimicrobial resistance pattern of main microorganisms in HAIs in Iran, 2018.
| Microorganism | Antibiotic | Resistance (%) | Interpretation |
|---|---|---|---|
| Staphylococcus aureus | Oxacillin / Cefoxitin | 49.29 | MRSA |
| Clindamycin | 59.77 | ||
| Vancomycin | 0.04 | ||
| Enterococcus spp. | Ampicillin | 55.88 | |
| Vancomycin | 56.56 | VRE | |
| Linezolid | 0.76 | ||
| Klebsiella pneumonia | 3rd or 4th generation cephalosporin | 80.41 | ESBL-producing |
| Fluoroquinolone | 68.19 | ||
| Beta-lactamase inhibitor | 71.63 | ||
| Carbapenem | 57.83 | KPC-producing | |
| Escherichia coli | 3rd or 4th generation cephalosporin | 70.16 | ESBL |
| Fluoroquinolone | 62.69 | ||
| Beta-lactamase inhibitor | 33.96 | ||
| Carbapenem | 21.45 | ||
| Pseudomonas Aeruginosa | Ceftazidime | 57.75 | |
| Fluoroquinolone | 56.57 | ||
| Aminoglycoside | 54.97 | ||
| Piperacillin/Tazobactam | 54.55 | ||
| Carbapenem | 60.06 | ||
| Acinetobacter baumannii | Ceftazidime | 93.76 | |
| Fluoroquinolone | 92.82 | ||
| Aminoglycoside | 89.18 | ||
| Ampicillin/Sulbactam | 68.05 | ||
| Carbapenem | 93.02 | ||
| Colistin | 3.81 |
HAI: Health care associated infection; MRSA: Methicillin-resistance Staphylococcus aureus; VRE: Vancomycin-resistant Enterococcus; ESBL: Extended spectrum beta-lactamase; KPC: Klebsiella pneumoniae carbapenemase.